• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

    1.220 +0.040 (+3.40%)
    Streaming Delayed Price Updated: 2:58 PM EDT, Jun 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 127,189
    Open 1.180
    Bid (Size) 1.220 (200)
    Ask (Size) 1.230 (12,600)
    Prev. Close 1.180
    Today's Range 1.170 - 1.250
    52wk Range 1.080 - 2.600
    Shares Outstanding 194,612,289
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
    Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -23.7%
    -23.7%
    1 Month
    -12.2%
    -12.2%
    3 Month
    -14.7%
    -14.7%
    6 Month
    -27.8%
    -27.8%
    1 Year
    -14.1%
    -14.1%

    More News

    Read More
    News headline image
    Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    News headline image
    Elon Musk Says Tesla, xAI Are 'Trending Towards Convergence' In Some Ways ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Aquestive Therapeutics Announces Leadership Expansion to Support Growth
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Tiziana Life Sciences Ltd - Common Shares publicly traded?
    Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.
    What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?
    Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?
    The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market
    What is the current price of Tiziana Life Sciences Ltd - Common Shares?
    The current price of Tiziana Life Sciences Ltd - Common Shares is 1.220
    When was Tiziana Life Sciences Ltd - Common Shares last traded?
    The last trade of Tiziana Life Sciences Ltd - Common Shares was at 06/04/26 02:58 PM ET
    What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?
    The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 237.45M
    How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?
    Tiziana Life Sciences Ltd - Common Shares has 237M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.